Verici Dx plc (AIM:VRCI) announced the publication of a peer-reviewed clinical validation study of its Pre-Transplant Rejection Assessment (PTRA) test in Kidney360.
The study, titled 'A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection,' evaluated the PTRA test's ability to predict Early Acute Rejection within two months post-transplant.
Commercially marketed by Thermo Fisher Scientific, the test outperformed conventional risk assessment tools. Dr. Beatrice Concepcion from University of Chicago Medicine stated: 'PTRA provides clinically meaningful, recipient-specific risk stratification.'
Note that the PTRA test is not FDA approved or CE marked. Bond.az ensures accuracy in reporting this development.
